
For adjunctive use with oestrogen in post-menopausal women with an intact uterus, as hormone replacement therapy.1

For oestrogen deficiency symptoms in postmenopausal women and prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis. The experience treating women older than 65 years is limited.2

Testogel is indicated in adults for testosterone replacement therapy for male hypogonadism when testosterone deficiency has been confirmed by clinical features and biochemical tests3,4

Luteal phase support during assisted reproductive technology cycles5,6

The UK’s first and only licensed progesterone treatment for preventing miscarriage in women with a history of recurrent miscarriage who present with bleeding in the first trimester7

For the treatment of endometriosis8

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Besins Healthcare (UK) Ltd Drug Safety on 0203 862 0920 or Email: drugsafety@besins-healthcare.com